创新药零售市场快速扩张，恒生创新药ETF（159316）最新规模超15亿元，创历史新高

Group 1 - The Hong Kong innovative drug sector opened high and fluctuated, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 0.5% as of 10:50 AM [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 200 million yuan, with a net subscription of 6 million units, and has seen over 500 million yuan in net inflows since August, reaching a historical high of over 1.5 billion yuan [1] - A recent report from the West Pharmaceutical 2025 DTP Pharmacy New Development Summit indicates that the retail pharmacy (DTP) innovative drug sales are expected to reach 88.7 billion yuan in 2024, representing a year-on-year growth of 16.6% [1] Group 2 - In the first quarter of 2025, the sales scale is projected to reach 23.3 billion yuan, with a year-on-year increase of 15.0%, indicating a sustained growth trend in innovative drug sales [1] - Shenwan Hongyuan pointed out that the revenue from innovative drug products and external licensing has maintained rapid growth over the past three years, with significant BD transactions occurring this year, leading to a trend of expanding the innovative drug market [1] - The recent revision of the Hang Seng Hong Kong Stock Connect Innovative Drug Index has officially taken effect, removing contract research organizations (CROs) and becoming the first index with a "purity" of 100% for innovative drugs [1]